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Background: Quiescent CD4+ T lymphocytes are highly refractory to HIV-1 infection due to a block at reverse
transcription.
Results: Examination of SAMHD1 expression in peripheral blood lymphocytes shows that SAMHD1 is expressed in
both CD4+ and CD8+ T cells at levels comparable to those found in myeloid cells. Treatment of CD4+ T cells with
Virus-Like Particles (VLP) containing Vpx results in the loss of SAMHD1 expression that correlates with an increased
permissiveness to HIV-1 infection and accumulation of reverse transcribed viral DNA without promoting
transcription from the viral LTR. Importantly, CD4+ T-cells from patients with Aicardi-Goutières Syndrome harboring
mutation in the SAMHD1 gene display an increased susceptibility to HIV-1 infection that is not further enhanced by
VLP-Vpx-treatment.
Conclusion: Here, we identified SAMHD1 as the restriction factor preventing efficient viral DNA synthesis in
non-cycling resting CD4+ T-cells. These results highlight the crucial role of SAMHD1 in mediating restriction of HIV-1
infection in quiescent CD4+ T-cells and could impact our understanding of HIV-1 mediated CD4+ T-cell depletion
and establishment of the viral reservoir, two of the HIV/AIDS hallmarks.
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The human immunodeficiency virus type-1 (HIV-1) pri-
marily infects CD4+ T-cells. While activated lymphocytes
support viral replication, non-cycling quiescent CD4+ T-
cells allow entry of HIV-1 but fail to allow efficient and
complete reverse transcription [1-6]. However, addition of
deoxynucleosides to unstimulated lymphocytes cultures
partially overcomes this failure [7-9], suggesting that an in-
sufficient supply of deoxynucleotide triphosphates (dNTPs)
in quiescent T-cells may, at least in part, contribute to
inefficient viral DNA synthesis [8,10]. Interestingly, the
Aicardi-Goutières syndrome gene product SAMHD1 was
recently described as the restriction factor that blocks
HIV-1 infection of non-cycling myeloid cells [11-13].
SAMHD1 is a dGTP-dependent deoxynucleotide tripho-
sphohydrolase [14-16] that reduces the cellular pool of
dNTPs in differentiated, non-cycling myeloid cells to levels* Correspondence: Benjamin.descours@igh.cnrs.fr; bmonsef@igh.cnrs.fr
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reproduction in any medium, provided the orbelow those required to support HIV-1 DNA synthesis
[15,17]. However, SAMHD1’s spectrum of activity beyond
cells of the myeloid lineage remains unclear.Results and discussion
We first determined whether SAMHD1 was expressed in
peripheral blood lymphocytes from healthy donors. West-
ern blot analysis revealed that both CD4+ and CD8+ T-
cells express SAMHD1 (Figure 1a). The expression levels
of SAMHD1 in unstimulated CD4+ T-cells were similar to
those found in myeloid cells, including CD14+ monocytes,
monocytes-derived macrophages (MDM) and monocyte-
derived dendritic cells (MDDC) (Figure 1a). Moreover,
flow cytometry analysis revealed that all circulating CD4+
T-cells subsets, including naïve (Tn; CD45RA+, CCR7+),
central memory (Tcm; CD45RA-, CCR7+) and effector
memory cells (Tem; CD45RA-, CCR7-), expressed high
levels of SAMHD1 (Figure 1b), raising the possibility that
SAMHD1 could affect the susceptibility of resting CD4+
lymphocytes to HIV-1 infection.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 CD4 T lymphocytes express SAMHD1. a. Western blot analysis of SAMHD1 expression in primary hematopoietic cells. b. Flow
cytometry analysis of SAMHD1 expression levels in CD14+ monocytes, T-cells (CD4+ and CD8+ T lymphocytes) and in CD4+ T-cell subsets
including Naïve (Tn; CD45RA+, CCR7+), Central Memory (Tcm; CD45RA-, CCR7+), and Effector Memory (Tem; CD45RA-, CCR7-). c. Kinetics of
SAMHD1 loss in quiescent (CD69-, HLA-DR-) CD4+ T-cells after VLP-Vpx treatment (representative experiment, n = 2). d. Vpx transduction of
activated CD4+ T-cells induces loss of SAMHD1. TCR-stimulated CD4+ T-cells were transduced with Vpx-HA expressing retroviral construct. Forty-
eight hours later, SAMHD1 and Vpx were immunostained using specific antibodies. Nuclei were stained in mounting media with DAPI. Pie charts
represent the proportions of SAMHD1+ cells among 100 Vpx positive and negative counted cells.
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ipheral blood mononuclear cells (PBMCs) to viral-like
particles containing the SIV accessory protein Vpxmac251
(VLP-Vpx), which counteracts SAMHD1-mediated re-
striction by triggering its proteasomal degradation
[12,13]. PBMCs treated with VLP-Vpx or empty VLPs
(VLP-Mock) were analyzed for SAMHD1 expression by
flow cytometry. An average of 16% of VLP-Vpx treated
resting CD4+ T-cells were SAMHD1 negative at 96 hours
post-exposure (Figure 1c), whereas most monocytes
(90.2%) lost the expression of SAMHD1 after 48 hrs of
VLP-Vpx treatment (Additional file 1: Figure S1). The
difference in Vpx-mediated loss of SAMHD1 in quies-
cent CD4+ T-cells and monocytes might result from dis-
crepancies in nuclear/cytoplasmic exchange [18]. Indeed,
we have recently shown that Vpx-mediated degradation
of SAMHD1 requires its nuclear export [19,20]. In sup-
port of this hypothesis, loss of SAMHD1 expression was
observed in more than 80% of T-cell receptor (TCR)-sti-
mulated CD4+ lymphocytes expressing Vpx (Figure 1d).
We next evaluated the effect of SAMHD1 loss on HIV-
1-resistance phenotype of resting CD4+ T-cells. Restric-
tion of HIV-1 replication in quiescent T-cells has been
attributed to blocks at both the reverse transcription
step and viral gene expression (e.g.: lack of transcription
factors such as NF-kB and CyclinT required for viral
transcription) [21,22]. Thus, to bypass the transcriptional
block, we performed single-round infection experiments
using an HIV-1 based lentiviral vector carrying an EGFP
cassette under the transcriptional control of the CMVpromoter (HIV-CMV-EGFP). Unstimulated PBMCs iso-
lated from healthy donors were exposed for 12 hrs to
VLP-Vpx or VLP-Mock and subsequently infected with
HIV-CMV-EGFP. As expected, no EGFP was detected
when cells were treated with VLP-Mock (Figure 2a), while,
VLP-Vpx treatment resulted in EGFP expression in quies-
cent (HLA-DR-, CD69-) CD4+ T-cells (Figure 2a). An
average of 14% of VLP-Vpx treated resting CD4+ T lym-
phocytes expressed EGFP, while less than 1% of cells
exposed to VLP-Mock were EGFP+ (Figure 2a and
Additional file 1: Figure S2a). As a control, VLP-Vpx treat-
ment enhanced the permissiveness of CD14+ monocytes
to HIV-CMV-EGFP (Additional file 1: Figure S3b). These
results indicate that Vpx could alleviate the post-entry
block to HIV-1 infection of unstimulated T-cells. Import-
antly, VLP-Vpx treatment was not associated with CD4+
T-cell activation (Additional file 1: Figure S2c) or prolif-
eration (Figure 2b). Vpx increased the susceptibility of
non-cycling quiescent T-cells (eFluorHigh) (Figure 2b)
while it had no effect on the permissiveness of activated
dividing T-cells (eFluorLow) despite high level expression
of SAMHD1 (Additional file 1: Figure S2d). In addition,
Vpx increased HIV-1 infection of all resting CD4+ T
subsets, including highly refractory naïve cells (Tn)
(Figure 2c).
We then focused our attention on viral reverse tran-
scription, which is initiated in most HIV-1 exposed T-
cell subsets [6]. Completion of this step is, nonetheless,
reached in resting CD4+ T-cells at a much slower rate
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Figure 2 Vpx treatment of quiescent CD4+ T-cells results in increased susceptibility to HIV-1 infection. a. Impact of Vpx treatment on
quiescent CD4+ T-cells susceptibility to HIV-CMV-EGFP infection. Upper right panel: expression vectors used to produce HIV-CMV-EGFP virions. Left
panel: PBMCs were treated 12 h with VLP-Mock or VLP-Vpx then infected with HIV-CMV-EGFP or uninfected (control). Proportions of EGFP positive
quiescent CD4+ T-cells (CD69- HLA-DR-) were assessed 4 days post infection. Lower right panel: Results are expressed as percentage of EGFP
positive cells. Graphic shows mean and standard deviation for 6 healthy donors. b. PBMCs were cultured as in a. after staining with the eFluor670
proliferation dye. Cell division and EGFP expression were assessed in CD4+ T-cells (a representative experiment is shown). c. Impact of Vpx on
quiescent CD4+ T-cell subsets susceptibility to HIV-CMV-EGFP infection. Left panel: gating strategy to define CD4+ T-cell subsets: Naïve (Tn;
CD45RA+, CCR7+), Central Memory (Tcm; CD45RA-, CCR7+) and Effector Memory (Tem; CD45RA-, CCR7-). Middle panel: Permissiveness of Tn, Tcm
and Tem to HIV-CMV-EGFP performed as described in a (a representative experiment; n = 3). d. Kinetics of full length HIV-CMV-EGFP DNA
accumulation quantified by quantitative PCR in purified non-stimulated CD4+ T-cells from 2 healthy donors #5 and #6. Proportions of EGFP
positive quiescent CD4+ T-cells (CD69- HLA-DR-) assessed by flow cytometry 4 days post infection by HIV-CMV-EGFP are indicated on the right. e.
Effect of Vpx on the permissiveness of quiescent CD4+ T-cells to infection by HIV-EGFP. Upper panel: expression vectors used to produce
HIV-EGFP virions. Lower left panel: PBMCs were cultured as in a. except cells were infected with HIV-EGFP. Proportions of EGFP positive quiescent
CD4+ T-cells (CD69- HLA-DR-) and CD14+ monocytes were assessed 4 days post infection for 3 donors. Lower right panel: Full length HIV-EGFP
DNA accumulation was performed as in d. for 1 donor.
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has been demonstrated for myeloid cells [13,17]. PBMCs
were exposed to VLP-Vpx or VLP-Mock and infected with
HIV-CMV-EGFP. The kinetics of reverse transcription
leading to production of full-length HIV-1 DNA in un-
stimulated CD4+ T-cells was determined by quantitative
PCR. We observed that both the amount and the rate of
reverse transcription leading to the production of full
length viral DNA were enhanced in Vpx treated resting
CD4+ T-cells compared to VLP-Mock treated counter-
parts (Figure 2d). These results show that VLP-Vpx over-
comes the restriction of HIV-CMV-EGFP infection in
resting CD4+ T-cells by promoting the accumulation of
full length reverse transcripts. We next verified whether
the observed effect of Vpx applies to wild type HIV-1. For
this purpose, unstimulated PBMCs were treated with
VLP-Mock or with VLP-Vpx and subsequently infected
with HIV-1 expressing EGFP (HIV-EGFP) (Figure 2e).
Following infection, we did not detect significant EGFP
expression in both VLP-Mock- and VLP-Vpx-treated rest-
ing CD4+ T-cells (Figure 2e and Additional file 1: Figure
S3a). This is consistent with the HIV-1 LTR transcrip-
tional block associated with their quiescent status and
confirms that the analyzed CD4+ T-cells are indeed in a
resting state. As a control, VLP-Vpx enhanced the permis-
siveness to HIV-EGFP of CD14+ monocyte population
(Figure 2e and Additional file 1: Figure S3a). A potential
infectivity defect was ruled out, since TCR-mediated acti-
vation of T-cells efficiently induced EGFP expression
(Additional file 1: Figure S3b). Interestingly, while no
EGFP positive cells were detected in resting CD4+ T-cells,
an accumulation of HIV-1 full length DNA was observed
in VLP-Vpx treated cells (Figure 2e). Thus, Vpx promotes
the accumulation of full-length viral DNA following the
infection of resting CD4+ T-cells, but does not relieve the
transcriptional block required for viral gene expression.
The ability of Vpx to promote infection was further
confirmed in another model of resting lymphocytes
(Additional file 1: Figure S4). Purified CD4+ T cells were
activated with PHA and cultured in IL-2 for 14-20 days,
until disappearance of the CD69 and Ki67 activation
markers [23]. Treatment of such cells with VLP-Vpx
induced SAMHD1 loss in a large fraction of the cells,
and a 6-fold increase in their sensitivity to HIV-CMV-
GFP infection (Additional file 1: Figure S4). Importantly,
the majority of infected EGFP-positive cells were found
in the SAMHD1-negative cell subset (Additional file 1:
Figure S4). Taken together, these results indicate that
Vpx, acting through SAMHD1, facilitates infection of
resting CD4+ T-cells by promoting the accumulation
of fully reverse transcribed viral DNA in quiescent
lymphocytes.
To confirm the role of SAMHD1 in the ability of Vpx to
overcome HIV-1 restriction in quiescent CD4+ T-cells, weused PBMCs isolated from 4 Aicardi-Goutières syndrome
patients harboring homozygous inactivating mutations in
the SAMHD1 gene (AGS-5, referred to as SAMHD1-/-)
[24]. Heterozygous donors for these SAMHD1 mutations
(referred to as SAMHD1-/+) were used as controls. We
first assessed the intrinsic susceptibility of unstimulated
SAMHD1-/- and SAMHD1-/+ CD4+ T-cells to HIV-CMV-
EGFP infection. While heterozygous deletion of SAMHD1
did not affect the intrinsic resistance of unstimulated
PBMCs to HIV-CMV-EGFP infection, homozygous dele-
tion increased the susceptibility of both quiescent CD4+
T-cells and monocytes (Figure 3a, b, c), indicating that
SAMHD1 is required to mediate HIV-1 restriction in rest-
ing CD4+ T-cells. Remarkably, VLP-Vpx treatment did
not further enhance permissiveness of SAMHD1-/- resting
CD4+ T-cells (Figure 3b, d). However, the restrictive
phenotype of SAMHD1-/+ cells is alleviated after VLP-Vpx
delivery (Figure 3a, d), indicating that SAMHD1 is
required for Vpx to overcome HIV-1 restriction in T-cells.
Overall, these results demonstrate that SAMHD1 acts as
an effective HIV-1 restriction factor in non-cycling resting
CD4+ lymphocytes.
Conclusion
The demonstration that SAMHD1 restricts HIV-1 repli-
cation in quiescent CD4+ T-cells could have an import-
ant implication in our understanding of HIV-1-mediated
CD4+ T-cell depletion and establishment of the viral res-
ervoir, two of the HIV/AIDS hallmarks. It has recently
been shown that abortive HIV-1 reverse transcription in
resting CD4+ T-cells leads to the accumulation of cyto-
plasmic viral nucleic acids that trigger a host defense
program eliciting a coordinated proapoptotic and proin-
flammatory response [25,26]. By preventing completion
of reverse transcription in quiescent CD4+ T-cells,
SAMHD1 could contribute to their depletion. The HIV-
1 reservoir, which mainly consists of quiescent CD4+ T-
cells that harbor integrated silent provirus, represents a
major barrier to viral eradication by antiretroviral therapy.
It has recently been shown that chemokines can facilitate
early steps of HIV-1 replication in resting CD4+ T-cells,
leading to latency [27]. It will be of importance to deter-
mine whether chemokines regulate SAMHD1 activity and
facilitate the generation of latently infected cells in vivo.
The regulation of SAMHD1 activity remains an important
area of study. In this regard, we observed that SAMHD1
restriction activity does not correlate with its expression
levels. Indeed, although SAMHD1 expression is independ-
ent of the activation state of CD4+ T-cell, its restriction ac-
tivity is witnessed only when the cells are in a quiescent
state (Additional file 1: Figure S2a and S2d). SAMHD1
activity could be regulated through post-translational
modifications and/or through the expression of a cellu-
lar partner in non-cycling cells, including quiescent
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Figure 3 Quiescent CD4+ T-cells from Aicardi-Goutières Syndrome patients, with inactivating mutation of SAMHD1 (AGS-5), display a
Vpx-independent susceptibility to HIV-1 infection. a. Impact of Vpx treatment on susceptibility to HIV-CMV-EGFP infection of quiescent CD4+
T-cells (CD69- HLA-DR-) and CD14+ monocytes from individuals with heterozygous AGS-5 SAMHD1-/+ mutation (n = 2). PBMCs were treated 12 h with
VLP-Mock or VLP-Vpx then infected with HIV-CMV-EGFP or left uninfected (control). Proportions of EGFP positive quiescent CD4+ T-cells were assessed
4 days post infection. b. PBMCs from AGS-5 SAMHD1-/- patients were treated and analyzed as in a. (n = 4). c. Impact of SAMHD1 homozygous mutation
on permissivity to HIV-CMV-EGFP infection of CD4+ T-cell (left panel) and monocytes (right panel). Results are expressed as a fold increase of GFP
positive cells among quiescent CD4+ T-cells, comparing SAMHD1-/- patients to SAMHD1-/+ individuals. d. Effect of Vpx treatment on the permissiveness
of quiescent CD4+ T-cell (left panel) and monocytes (right panel) derived from SAMHD1-/- patients (n = 3) and SAMHD1-/+ (n = 1) to HIV-CMV-EGFP.
Results are presented as fold increase comparing the percentage of GFP positive cells in VLP-Vpx to VLP-Mock treated samples.
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regulated through the expression of splice variants lacking
the enzymatic activity [28]. Given that dN supply only par-
tially rescues HIV-1 reverse transcription in resting CD4+
T-cells, one can ask whether the restriction imposed by
SAMHD1 is fully or partially due to its dNTP triphospho-
hydrolase activity. Interestingly, it has recently been shown
that SAMHD1 is a nucleic acid binding protein that dis-
plays a preference for RNA over DNA [29]. Further stud-
ies are required to elucidate the mechanism by which
SAMHD1 restricts HIV-1 in resting CD4+ T-cells. Deci-
phering the functional interaction between HIV-1 and
SAMHD1 will lead to a better understanding of the dam-
age imposed by this virus to the immune system and the
progression towards AIDS.Methods
Cell extract and western blot analysis
CD14+ and CD4+ T-cells were purified using CD14+
microbeads or CD4+ T-cell isolation kit (Miltenyi Bio-
tec). CD14+ monocytes were treated 2 hours with VLP-
Vpx before preparation of whole cell extracts (WCE).
WCE were prepared with buffer containing 0.5% Triton
X-100, 150 mM NaCl, 10 mM KCL, 1.5 mM MgCl2,
0.5 mM EDTA 10 mM β-mercaptoethanol, 0.5 mM
PMSF. Cell lysates were boiled in SDS sample buffer and
resolved on a SDS-PAGE gel (Biorad). Proteins were
liquid-transferred (Biorad) to nitrocellulose membrane
in transfer buffer (20% methanol, 25 mM Tris, 192 mM
Glycine, 0.037% SDS) during 90 min at 100 V. Western
blotting was performed using the following antibodies:
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anti-Erk1/2 (Cell Signaling Technology).
Immunofluorescence
Purified CD4+ T-cells were stimulated for 3 days with
anti-CD3, anti-CD28 and IL-2 and transduced with Vpx
expressing retroviral construct [13]. Two days post
transduction, cells were harvested and fixed in PBS with
4% paraformaldehyde and 2% sucrose, and permeabilized
with 0.5% Triton X-100, 20 mM Tris (pH 7.6), 50 mM
Nacl, 3 mM MgCl2, and 300 mM sucrose. Wash and
antibody incubation steps were performed in PBS-0.1%
Tween. Cells were stained with Anti-SAMHD1 (Abcam
#AB67821) and Vpx was stained with anti-HA (Cov-
ance). Secondary antibodies were purchased from Invi-
trogen. Nuclei were stained with DAPI in mounting
media (Vectashield; Vector Labs) and images were col-
lected on a Zeiss Axioimager Apotome.
Plasmids
SIV3+ was kindly provided by N. Manel. SIV- was a gift
from J. Luban. HA-Vpxmac251 was subcloned in pOz-
IL2Rα expression vector. pHRET was kindly provided by
C. Mettling. pBR-NL4-3-IRES-EGFP was a gift of F.
Kirchhoff. psPAX2 packaging plasmid was obtained from
Addgene (D. Trono). MMLV packaging plasmid, A-MLV
envelope and pMD2-G VSV-G envelope were previously
described [13].
Virus-Like Particles (VLP) and virus production
VLPs and viral particles were produced from 293 T-cells
using the standard phosphate calcium transfection
protocol. For VLPs, 293 T-cells were transfected with
8 μg SIV3+and 2 μg pMD2-G VSV-G encoding plasmid
(VLP-Vpx) or with 8 μg SIV- and 2 μg pMD2-G (VLP-
Mock). Media were replaced 16 h after transfection, and
VLPs were harvested 48 h later, filtered at 0.45 μm and
concentrated 100 times by ultracentrifugation. For virus
production, HIV-EGFP was produced by transfection of
10 μg of pBR-NL4-3-IRES-EGFP and 1 μg of pMD2-G.
HIV-CMV-EGFP was produced by transfection of 5 μg
of pHRET, 5 μg of psPAX2 packaging vector, and 2.5 μg
of pMD2-G. For MLV transduction particles, 293 T-cells
were transfected with 5 μg pOz HA-Vpxmac251 construct,
2.5 μg MMLV packaging plasmid, and 2.5 μg A-MLV en-
velope encoding plasmid. When required, p24 concen-
tration was measured by ELISA (Innogenetics).
Infection
PBMCs were isolated from blood samples by Ficoll gra-
dient (Eurobio), cultured 12 h in presence of VLP-
Vpxmac251 or VLP-Mock at a density of 2 million cells
per well (24 well plates) in 300 μl of 10% FCS supple-
mented complete RPMI (R10) (Invitrogen). Infectionwas then performed by addition of 300 μl of R10 diluted
HIV-CMV-EGFP (1 μg) or HIV-EGFP (800 ng) for 4 days
before analysis. As control, TCR stimulated PBMCs were
cultured for 3 days on plate-bound anti-CD3 antibody
(5 μg/ml) (Miltenyi Biotec) in presence of 1 μg/ml anti-
CD28 antibody and IL-2 (20U/ml) (Roche) and infected
with HIV-CMV-EGFP (1 μg) or HIV-EGFP (800 ng) for
2 days before analysis. Optimal viral inoculums were
determined by titration using TCR stimulated PBMCs.
Alternatively, after thawing, Trypan Blue viability assess-
ment and TURBO™ DNase (Ambion) treatment at 37°C
for 1 hour were performed, and cryopreserved PBMCs
were cultured in aforementioned conditions.
Flow cytometry
Non-cycling, quiescent CD4+ T-cells and monocytes were
analyzed using the following antibodies and dye: Brilliant-
Violet421 anti-CD3 (UCHT1), PeCy7 anti-CD4 (RPA-T4),
PE anti-CD69 (FN50), APC anti-HLA-DR (TU36), V500
anti-CD14 (M5ED), PeCy7 anti-CCR7 (3D12), PE anti-
CD45RA (HI100) (BD Biosciences), PerCP anti-CD45
(5B1) (Miltenyi Biotec), Cell-Proliferation Dye eFluorW
670 (eBiosciences) and Alexa-488 Anti-SAMHD1 (I-1918)
(O. Schwartz). Cells were analyzed on MACSQuant
Analyzer (Milteny Biotec). Data analyses were per-
formed on FlowJo (TreeStar inc).
Quantification of viral full-length DNA
Prior infection, viral stocks were treated for 1 h at 37°C
with 100U/ml of TURBO™ DNase (Ambion). PBMCs (2
X 106 cells) were infected with 1000 ng of HIV-CMV-
EGFP or with heat inactivated HIV-CMV-EGFP. CD4+
T-cells were purified from cultured PBMCs by depleting
non CD4+ T-cell, using CD4+ T-cell isolation kit (Milte-
nyi Biotec) (Average purification yield of 97%). Genomic
DNA was extracted using the QIAmp DNA blood mini-
kit (Qiagen). Full-length viral DNA quantification was
performed by quantitative PCR using primers annealing
in the 5’LTR-U5 and gag regions. PCR measurements
were performed in duplicate using SYBR Green (Qia-
gen). Amplifications were carried out in the LightCy-
cler480 (Roche). The average of the technical duplicates
was normalized to GAPDH levels using the comparative
CT method (2ΔΔCT).
Preparation of resting post-activated CD4+ T cells and
lentiviral vector transduction
CD4+ T cells were isolated by positive selection as
described above (Miltenyi Biotec). Resting CD4+ T cells
were activated with 1ug/ml phytohemagglutinin (PHA)
and 100 U/ml Interleukin 2 (IL-2) and cultured in fresh
medium containing IL-2 for 14 to 20 days [23]. The ac-
tivation state was monitored every few days by flow
cytometry after staining with PE-coupled CD69 and
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activated cells were treated with Vpx-VLPs or Mock-
VLPs for 3 hours, washed and incubated overnight with
HIV-CMV-EGFP. The following day, cells were washed
and incubated in fresh medium containing IL-2 for
96 hours. Percentages of EGFP positive and SAMHD1
negative cells were then assessed by flow cytometry.
Additional file
Additional file 1: SAMHD1 restricts HIV-1 replication in quiescent
CD4+ T-cells.
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